Clinical significance of acquired somatic mutations in aplastic anaemia

International Journal of Hematology

Volumn 104, Issue 2, 2016, Pages 159-167

  Marsh, J C W ^a   Mufti, G J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

AML; Aplastic anaemia; Clonal haemopoiesis; MDS; Somatic mutations

Indexed keywords

APLASTIC ANEMIA; CLONAL CYTOPENIA OF UNCERTAIN SIGNIFICANCE; CLONAL HAEMOPOIESIS OF INDETERMINATE PROGNOSIS; CYTOPENIA; HEMATOPOIESIS; HUMAN; MOLECULAR CLONING; PROGNOSIS; REVIEW; SOMATIC MUTATION; CELL CLONE; GENETICS; MUTAGENESIS; PATHOLOGY;

ANEMIA, APLASTIC; CLONE CELLS; HUMANS; MUTAGENESIS;

EID: 84963762350     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-1972-8     Document Type: Review

References (43)

1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anaemia. Blood. 2006;108:2509–19.
2. Young NS, Bacigalupo A, Marsh JCW. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1):S119–25.
3. Kordasti S, et al. Functional characterization of CD4+ T-cells in Aplastic Anemia. Blood. 2012;119:2033–43.
4. Bennett JM, Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009;94:264–8.
5. Gupta V, et al. Clinical relevance of cytogenetics abnormalities in adult patients with acquired aplastic anaemia. Br J Haematol. 2006;134:95–9.
6. Jerez A, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453–9.
7. Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–7.
8. Papaemmanuil E, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome; Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.
9. Maciejewsk JP, et al. Impaired hematopoiesis in paroxysmal nocturnal haemoglobinuria/aplasticanemia is not associated with a selective proliferative defect in the glycosylphosphatidyl-inositol-anchored protein-deficient clone. Blood. 1997;89:1173–81.
10. Murakami Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidyl-inositol-anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–22.
11. Risitano AM, et al. Large granular lymphocyte (LGL)- like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia. 2005;19:217–22.
12. Va Bijnen ST, et al. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. Exp Hematol. 2011;39:751–62 (e1–3).
13. Gargiulo L, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:2753–61.
14. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109:2399–405.
15. Hosokawa K, et al. Increased glycosylphosphatidylinositol-anchored protein-deficient granulocytes define a benign subset of bone marrow failures in patients with trisomy 8. Eur J Hematol. 2015;95:230–8.
16. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118:6601–9.
17. Hosokawa K, Katagiri T, Sugimori N, et al. Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO ‘MDS-U’ designation. Haematologica. 2012;97:1845–9.
18. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
19. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.
20. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.
21. Schlush LI, et al. Aging, clonal hematopoiesis and pre-leukemia: not just bad luck? Int J Hematol. 2015;102:513–22.
22. Steensma, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndrome. Blood. 2015;126:9–16.
23. Lane AA, et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013;27:968–71.
24. Heuser M, et al. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica. 2014;99(9):e165–7.
25. Babushok DV, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208:115–28.
26. Kulasekararaj AG, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–704.
27. Yoshizato T, et al. Somatic mutations and clonal hematopoiesis in aplastic anaemia. N Eng J Med. 2015;373:35–47.
28. Dumitriu B, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood. 2015;125:706–9.
29. Kwok B, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015;126:2355–61.
30. Mufti GJ, Kulasekararaj AG, Marsh JC. Somatic mutations and clonal hematopoiesis in Aplastic Anemia. N Engl J Med. 2015;373:1674–5.
31. Risitano AM, et al. The RACE study: a SAAWP prospective randomized multicenter study comparing horse antithymocyte globulin (hATG) + cyclosporine A (CsA) with or without eltrombopag as front-line therapy for severe aplastic anaemia patients (WP007). Bone Marrow Transplant. 2015;50(S1):pS99.
32. Olnes MJ, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
33. Desmond, et al. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug. Blood. 2014;123:1818–25.
34. Marsh JC, Mufti GJ. Eltrombopag: a stem cell cookie? Blood. 2014;20(123):1774–5.
35. Scheinberg P, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358–64.
36. Scheinberg P, et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16.
37. Bacigalupo A, et al, for the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Current outcome of HLA identical sibling vs. unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015; 100: 696–702.
38. Marsh JC, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118:2351–7.
39. Grimaldi, et al. King’s College Hospital FCC conditioning for severe aplastic anemia induces tolerance with mixed T-cell chimerism and extremely low incidence of Gvhd. Blood (Annual Scientific Meeting). 2014;124:1594.
40. Samarasinghe S, et al. Impact of different in vivo T cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anaemia: a study on behalf of the EBMT SAA Working Party. Blood (Annual Scientific Meeting). 2015;126(23):1210.
41. Socié G, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329:1152–7.
42. Kojima S, et al. Japan Childhood Aplastic Anemia Study Group. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100(3):786–90.
43. Kordasti S, et al. High resolution mass cytometry (CyTOF) in aplastic anaemia (AA) can identify an aberrant Treg subset with pro-inflammatory properties, predicting poor response to immunosuppressive therapy. Blood. 2014;124:1600 (Annual Scientific Meeting of American Society of Hematology).